Patents by Inventor Sudhir Agrawal

Sudhir Agrawal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of toll-like receptor 5 expression by antisense oligonucleotides
    Patent number: 8153777
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR5. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR5 expression and for prevention or treatment of diseases wherein modulation of TLR5 expression would be beneficial are provided.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: April 10, 2012
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Lakshmi Bhagat, Daqing Wang, Dong Yu, Sudhir Agrawal
  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
    Patent number: 8153608
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: April 10, 2012
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Lakshmi Bhagat, Dong Yu, Ekambar R. Kandimalla
  • NOVEL AGONISTS OF TOLL-LIKE RECEPTOR 3 AND METHODS OF THEIR USE
    Publication number: 20120034248
    Abstract: TLR3 agonist compounds, compositions and methods are provided for stimulating the activity of TLR3. The compositions comprise oligonucleotide-based compounds that bind to and activate TLR3. The compositions may also comprise oligonucleotide-based compounds that bind to and activate TLR3 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for stimulation of TLR3 activity and for prevention or treatment of diseases wherein modulation of TLR3 activity would be beneficial are provided.
    Type: Application
    Filed: June 24, 2011
    Publication date: February 9, 2012
    Inventors: EKAMBAR R. KANDIMALLA, TAO LAN, VICTORIA JANE PHILBIN, SUDHIR AGRAWAL
  • Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
    Patent number: 8106173
    Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: January 31, 2012
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Tao Lan, Yukui Li, Dong Yu, Daqing Wang, Mallikarjuna Reddy Putta, Sudhir Agrawal
  • COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF
    Publication number: 20120016004
    Abstract: The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies.
    Type: Application
    Filed: March 2, 2011
    Publication date: January 19, 2012
    Inventors: SUDHIR AGRAWAL, EKAMBAR KANDIMALLA, MALLIKARJUNA PUTTA, TAO LAN, LAKSHMI BHAGAT, DAQING WANG, DONG YU
  • NOVEL SYNTHETIC AGONISTS OF TLR9
    Publication number: 20110311518
    Abstract: The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.
    Type: Application
    Filed: June 8, 2011
    Publication date: December 22, 2011
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: EKAMBAR R. KANDIMALLA, MALLIKARJUNA PUTTA, DAQING WANG, DONG YU, LAKSHMI BHAGAT, SUDHIR AGRAWAL
  • IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS COMPRISING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
    Publication number: 20110305684
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunostimulatory oligonucleotides according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: May 5, 2010
    Publication date: December 15, 2011
    Inventors: Sudhir Agrawal, Dong Yu, Ekambar Kandimalla
  • NOVEL SYNTHETIC AGONISTS OF TLR9
    Publication number: 20110293565
    Abstract: The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.
    Type: Application
    Filed: January 28, 2010
    Publication date: December 1, 2011
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Daqing Wang, Dong Yu, Lakshmi Bhagat, Sudhir Agrawal
  • Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
    Patent number: 8030462
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: October 4, 2011
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS
    Publication number: 20110229456
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: December 1, 2010
    Publication date: September 22, 2011
    Inventors: SUDHIR AGRAWAL, EKAMBAR R. KANDIMALLA, DONG YU, LAKSHMI BHAGAT
  • Stabilized immunomodulatory oligonucleotides
    Patent number: 8008267
    Abstract: The invention provides immunostimulatory oligonucleotides having at least one CpG dinucleotide and a secondary structure at the 5?- or 3?-end. These oligonucleotides have either reduced or improved immunostimulatory properties. The invention establishes that 5?-terminal secondary structures affect immunostimulatory activity significantly more than those at the 3?-end. The invention also provides methods for increasing or decreasing the immunostimulatory activity of a CpG-containing nucleic acid.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: August 30, 2011
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Lakshmi Bhagat, Rajendra K. Pandey, Dong Yu, Sudhir Agrawal
  • Potentiation of Autoimmune and Inflammatory Disease Treatments by Immune Regulatory Oligonucleotide (IRO) Antagonists of TLR7 and TLR9
    Publication number: 20110171209
    Abstract: The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs and potentiators of anti-inflammatory agents that inhibit TNF for the prevention and treatment of inflammatory and autoimmune diseases.
    Type: Application
    Filed: June 1, 2010
    Publication date: July 14, 2011
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Fu-Gang Zhu, Ekambar Kandimalla, Sudhir Agrawal
  • SYNERGISTIC STIMULATION OF THE IMMUNE SYSTEM USING IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND/OR IMMUNOMER COMPOUNDS IN CONJUNCTION WITH CYTOKINES AND/OR CHEMOTHERAPEUTIC AGENTS OR RADIATION THERAPY
    Publication number: 20110158937
    Abstract: The invention provides optimized methods and compositions for enhancing the immune response caused by immunostimulatory compounds used for the treatment of disease such as, but not limited to, treatment of cancer, autoimmune disorders, asthma, respiratory allergies, food allergies and infectious diseases in a patient. The optimized methods according to the invention provide synergy between the therapeutic effects of immunostimulatory oligonucleotides and immunomer compounds in accordance with the invention, and the therapeutic effect of cytokine immunotherapy and/or chemotherapeutic agents and/or radiation.
    Type: Application
    Filed: April 9, 2010
    Publication date: June 30, 2011
    Inventors: Ekambar Kandimalla, Sudhir Agrawal
  • MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
    Publication number: 20110150863
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: November 23, 2010
    Publication date: June 23, 2011
    Inventors: Sudhir Agrawal, Lakshmi Bhagat, Dong Yu, Ekambar R. Kandimalla
  • Synthetic agonists of TLR9
    Patent number: 7960362
    Abstract: The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: June 14, 2011
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Daqing Wang, Dong Yu, Lakshmi Bhagat, Sudhir Agrawal
  • SYNTHETIC AGONISTS OF TLR9
    Publication number: 20110135669
    Abstract: The invention provides novel oligonucleotide-based compounds that individually provide distinct immune response profiles through their interactions as agonists with TLR9. The TLR9 agonists according to the invention are characterized by specific and unique chemical modifications, which provide their distinctive immune response activation profiles.
    Type: Application
    Filed: December 3, 2010
    Publication date: June 9, 2011
    Inventors: EKAMBAR KANDIMALLA, MALLIKARJUNA PUTTA, DONG YU, LAKSHMI BHAGAT, DAQING WANG, SUDHIR AGRAWAL
  • POTENT MUCOSAL IMMUNE RESPONSE INDUCED BY MODIFIED IMMUNOMODULATORY OLIGONUCLEOTIDES
    Publication number: 20110123540
    Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers on mucosal innate immunity as well as adjuvant activity using ovalbumin (OVA) as an antigen through administration to the mucosal lining.
    Type: Application
    Filed: November 23, 2010
    Publication date: May 26, 2011
    Inventors: Daqing Wang, Ekambar Kandimalla, Sudhir Agrawal, Fu-Gang Zhu
  • Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
    Patent number: 7932367
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: April 26, 2011
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF
    Publication number: 20110082186
    Abstract: The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies.
    Type: Application
    Filed: August 26, 2010
    Publication date: April 7, 2011
    Applicant: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Mallikarjuna Putta, Tao Lan, Lakshmi Bhagat, Daqing Wang, Dong Yu
  • MODULATION OF OLIGONUCLEOTIDE CPG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
    Publication number: 20110059067
    Abstract: The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.
    Type: Application
    Filed: November 8, 2010
    Publication date: March 10, 2011
    Inventor: SUDHIR AGRAWAL